Search

Grifols SA

Closed

SectorFinance

10.16 1.04

Overview

Share price change

24h

Current

Min

10.025

Max

10.28

Key metrics

By Trading Economics

Income

-25M

73M

Sales

-282M

1.7B

P/E

Sector Avg

16.374

18.576

EPS

0.107

Profit margin

4.294

Employees

25,000

EBITDA

78M

353M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-0.6% downside

Dividends

By Acuity

Next Earnings

3 lis 2026

Next Dividend date

12 sie 2026

Next Ex Dividend date

10 sie 2026

Market Stats

By TradingEconomics

Market Cap

495M

6.6B

Previous open

9.12

Previous close

10.16

News Sentiment

By Acuity

31%

69%

89 / 438 Ranking in Finance

Grifols SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 23:56 UTC

News

Diversified Healthcare Trust reported second-quarter FFO of $0.16, exceeding estimates. Revenue fell short at $365.39 million, contributing to a decline in after-market trading.

3 sie 2026, 23:56 UTC

News

First Solar Inc reported second-quarter revenue of $1.06 billion and a net profit of $423 million. Shares are higher in after-hours trading.

3 sie 2026, 23:52 UTC

Social Media
Correlated Moves
News

Microsoft shares are lower in after-market hours amid a class action lawsuit alleging misrepresentation of its Copilot products' performance and competitive position.

3 sie 2026, 23:51 UTC

News

Marvell Technology plans a conference call for August 27, 2026, and an Investor Day on October 6, 2026. Shares are higher in after-market trading.

3 sie 2026, 23:51 UTC

News

Rivian Automotive raises 2026 capital expenditure guidance to $1.7B-$1.8B, shares trade higher in after-market hours amid focus on cost management and production scaling.

3 sie 2026, 23:51 UTC

News

JELD-WEN Holding Inc. reported second-quarter revenue of $817.8 million, exceeding forecasts. The company raised its full-year revenue guidance, boosting after-market trading sentiment.

3 sie 2026, 23:51 UTC

Social Media
News

Palantir Technologies reported Q2 revenue of $1.94 billion, exceeding expectations. Shares rose sharply in after-market hours following strong earnings and raised guidance.

3 sie 2026, 23:51 UTC

Social Media
News

Snap Inc. reported a narrower net loss of $163.96 million and revenue of $1.60 billion, exceeding expectations. Shares rose during after-market trading.

3 sie 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

3 sie 2026, 23:46 UTC

News

CVS Health shares rose in after-market hours following a survey showing increased provider-payer trust scores and improved perceptions of digital tools in healthcare.

3 sie 2026, 23:46 UTC

News

Alexandria Real Estate Equities reported a narrower net loss and FFO of $1.73, exceeding estimates. Shares traded higher in after-market hours.

3 sie 2026, 23:46 UTC

Correlated Moves
News

Nova Ltd's after-market shares are higher, bolstered by strong analyst sentiment and a consensus price target of $603.38, reflecting a potential 54.4% return.

3 sie 2026, 23:46 UTC

News

Realty Income Corp reported first-quarter revenue of nearly $1.55 billion, with adjusted funds from operations increasing to $1.06 billion. Shares were roughly flat after-market.

3 sie 2026, 23:41 UTC

News

Teladoc Health remains effectively unchanged in after-market trading. Citigroup lowered its price target from $11.00 to $7.50 while maintaining a "neutral" rating.

3 sie 2026, 23:41 UTC

News

Addus Homecare Corp reported Q2 revenue of $377.4 million and adjusted EPS of $1.73. Shares declined after the earnings announcement amid mixed market reactions.

3 sie 2026, 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

3 sie 2026, 23:41 UTC

Correlated Moves
News

DA Davidson raised its price target for First Business Financial Services to $80, contributing to higher shares in after-market trading.

3 sie 2026, 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

3 sie 2026, 23:41 UTC

News

Andersons Inc. shares rise in after-market trading following strong Q2 results, with adjusted net income of $73.6 million exceeding expectations.

3 sie 2026, 23:41 UTC

Social Media
News

BWX Technologies shares are lower in after-market hours following a revenue miss of $901.6 million and a divestiture of its medical business to Nordic Capital.

3 sie 2026, 23:41 UTC

Social Media
News

Williams Companies announced an agreement to acquire Momentum Midstream for up to $5.5 billion, boosting its natural gas infrastructure and supporting Gulf Coast demand.

3 sie 2026, 23:41 UTC

News

Ichor Holdings shares lower in after-market trading following a revenue miss of $294.8 million and EPS of $0.03, below expectations.

3 sie 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

3 sie 2026, 23:31 UTC

News

Ameresco shares rose in after-market trading following strong Q2 results, with revenues of $515.5 million exceeding expectations and a record $1.8 billion in new project awards.

3 sie 2026, 23:31 UTC

News

UBS raised its price target on Colgate-Palmolive Co to $109, maintaining a Buy rating. Shares are trading higher in after-market hours.

3 sie 2026, 23:31 UTC

Social Media
News

Grab Holdings reported strong Q2 results, with earnings per share of 6 cents and revenue of $997 million. Shares are higher in after-market hours.

3 sie 2026, 23:31 UTC

News

Ultra Clean Holdings reported Q2 net income of $11.9 million and revenue of $644.9 million, raising its Q3 outlook to between $700 million and $750 million.

3 sie 2026, 23:26 UTC

Social Media
News

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

3 sie 2026, 23:21 UTC

News

Banner Corp announces a buyback of up to 1.7 million shares, aiming to enhance long-term shareholder value. Shares are higher in after-market trading.

3 sie 2026, 23:21 UTC

News

Inspire Medical Systems reported Q2 adjusted EPS of $0.14, exceeding expectations. The company raised its full-year EPS guidance to between $1.05 and $1.45.

Peer Comparison

Price change

Grifols SA Forecast

Price Target

By TipRanks

-0.6% downside

12 Months Forecast

Average 10 EUR  -0.6%

High 10 EUR

Low 10 EUR

Based on 1 Wall Street analysts offering 12 month price targets forGrifols SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Sentiment

By Acuity

89 / 438 Ranking in Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat